2bq6: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Structure-activity relationships within a series of highly potent, 2-carboxyindole-based factor Xa inhibitors incorporating a neutral P1, ligand are described with particular emphasis on the structural, requirements for addressing subpockets of the factor Xa enzyme., Interactions with the subpockets were probed by systematic substitution of, the 2-carboxyindole scaffold, in combination with privileged P1 and P4, substituents. Combining the most favorable substituents at the indole, nucleus led to the discovery of a remarkably potent factor Xa inhibitor, displaying a K(i) value of 0.07 nM. X-ray crystallography of inhibitors, bound to factor Xa revealed substituent-dependent switching of the, inhibitor binding mode and provided a rationale for the SAR obtained., These results underscore the key role played by the P1 ligand not only in, determining the binding affinity of the inhibitor by direct interaction, but also in modifying the binding mode of the whole scaffold, resulting in, a nonlinear SAR. | Structure-activity relationships within a series of highly potent, 2-carboxyindole-based factor Xa inhibitors incorporating a neutral P1, ligand are described with particular emphasis on the structural, requirements for addressing subpockets of the factor Xa enzyme., Interactions with the subpockets were probed by systematic substitution of, the 2-carboxyindole scaffold, in combination with privileged P1 and P4, substituents. Combining the most favorable substituents at the indole, nucleus led to the discovery of a remarkably potent factor Xa inhibitor, displaying a K(i) value of 0.07 nM. X-ray crystallography of inhibitors, bound to factor Xa revealed substituent-dependent switching of the, inhibitor binding mode and provided a rationale for the SAR obtained., These results underscore the key role played by the P1 ligand not only in, determining the binding affinity of the inhibitor by direct interaction, but also in modifying the binding mode of the whole scaffold, resulting in, a nonlinear SAR. | ||
==Disease== | |||
Known disease associated with this structure: Factor X deficiency OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227600 227600]] | |||
==About this Structure== | ==About this Structure== | ||
| Line 45: | Line 48: | ||
[[Category: zymogen]] | [[Category: zymogen]] | ||
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov | ''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 21:04:54 2007'' | ||